We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » IVAX RECEIVES FIRST-FILER STATUS ON GENERIC GLUCOVANCE
IVAX RECEIVES FIRST-FILER STATUS ON GENERIC GLUCOVANCE
February 19, 2004
The FDA has granted generic firm Ivax final approval to market a version of Bristol-Myers Squibb’s (BMS’) Type 2 diabetes drug Glucovance (glyburide/metformin HCl), Ivax said yesterday.